Cisplatin Shortage May be Eased by Chinese Company
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
MONDAY, June 5, 2023 -- With the United States facing a high number of drug shortages, a Chinese company may help to boost the supply of one in particular, the chemotherapy agent cisplatin.
The U.S. Food and Drug Administration is working with the Chinese drugmaker Qilu Pharmaceutical to import the widely used cancer drug. The Canadian pharmaceutical company Apotex will distribute the medication in 50-mg vials, CNN reported. Health care providers can begin ordering the drug on Tuesday.
"The FDA recognizes the importance of a stable, safe supply of critical drugs used in oncology, especially those used in potentially curative or life-extending situations," said FDA Commissioner Robert Califf, M.D., on Twitter late Friday. "Today, we've taken steps for temporary importation of certain foreign-approved versions of cisplatin products from FDA-registered facilities and used regulatory discretion for continued supply of other cisplatin and carboplatin products to help meet patient needs."
Califf stressed that in these situations regulators carefully assess product quality and require companies to take certain measures to ensure the products are safe for patients.
"The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages," he added.
The near-record number of drug shortages has had a big effect on cancer treatments, with about two dozen chemotherapy drugs in active shortage this spring, CNN noted, citing data from the University of Utah Drug Information Service. Lawmakers criticized the FDA for falling behind on inspections of international facilities in a hearing last month, but the agency said much of the shortages were due to economics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
Living Outside of Comprehensive Cancer Center Catchment Area Tied to Later-Stage Diagnosis
TUESDAY, May 28, 2024 -- Disadvantaged populations and those living outside of a comprehensive cancer center's main catchment area have higher odds of receiving a diagnosis of...
Disparities Seen in Cancer Treatment Delivery at Minority-Serving Hospitals
TUESDAY, May 28, 2024 -- There are systemic disparities in definitive cancer treatment delivery at minority-serving hospitals (MSHs) versus non-MSHs, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.